Pipeline

90 programs available for collaboration.

Across autoimmune, oncology, metabolic, and CNS, mAb, bispecific, trispecific, ADC, GPCR nanobody. All designed on AINN-P1 and wet-lab validated. Full data room under CDA.

mAb / VHH Bispecific / Trispecific ADC GPCR Ab / Nanobody
DiscoveryLead IDLead opt.Preclinical

Autoimmune & Anti-inflammatory

27 programs
mAb programs
13 targets · mAb / VHH

CD122, TL1A, IL-23 p19, A4B7, BAFFR, FcRn, TMEM219, TSLP, IL-33, IL-13, IL-25, IL-36R, IL-18

Bispecific programs
12 programs · Bi-specific

CD122×TL1A, A4B7×IL-23, TSLP×IL-13, IL-25×IL-13, TMEM219×TL1A, IL-23×TL1A, BAFFR×TL1A, and additional combinations

Trispecific antibodies
2 programs · Tri-specific

IL-33 × TSLP × IL-13 · TSLP × IL-25 × IL-13

Oncology

28 programs
mAb programs
13 targets · mAb / VHH

PD-L1, TROP2, VEGF, GPNMB, B7-H3, HHLA2, EPHA5, DLK1, MELTF, MUC16, DLL3, CD200, IGF2

Bispecific programs
6 programs · Bi-specific

PDL1×HHLA2, PDL1×EPHA5, DLK1×EPHA5, PDL1×DLK1, MELTF×VEGF, DLK1×VEGF

Trispecific antibody
1 program · Tri-specific

PDL1 × TROP2 × VEGF

Antibody-drug conjugates
8 programs · ADC

PDL1×TROP2, TROP2×VEGF, PDL1×B7H3, PDL1×GPNMB, MELTF, DLK1×VEGF, PDL1×EPHA5, PDL1×DLK1

Metabolic

Advanced lead-optimization stage
ActRII A/B programs*
2 targets · mAb / VHH

ActRII A/B, Myostatin, lead candidates advancing toward animal studies.

CNS, Neuroregeneration & Addiction

4 targets
mAb programs*
4 targets · mAb / VHH

CD98 (BBB shuttle, animal discussions underway), Nogo-A, HMGB1, GDF15

GPCR Antibody & Nanobody

29 targets
Ab / Nanobody
29 targets · GPCR

GLP1R, GIPR, GCGR, CCR8, CCR5, CCR2, CXCR2–6, S1PR1, ADORA2A, MC4R, C5AR1, PAR2/4, and more

* Lead candidates advancing to animal studies. Stages shown are discovery through preclinical. No clinical-stage programs are represented on this summary. All affinities cited elsewhere on the site are from AINN-P1-designed campaigns measured by SPR or BLI. Full data available under CDA.

Platform foundation

AINN-P1 powers sequence-first collaboration.

AINN-P1 is a 167M-parameter protein foundation model built for sequence-to-function prediction without requiring 3D modeling. Specialized downstream models support binding, immunogenicity, stability, and epitope mapping across every pipeline program above.

Read the AINN-P1 preprint →
Data room

Ready to see the wet-lab data behind these programs?

Pick any target or program above. Under CDA, we'll share binding data, FTO analysis, and the development plan within one week.

Request the data room →